लोड हो रहा है...
Severe infusion reaction due to nivolumab: A case report
BACKGROUND: Nivolumab is an anti‐PD1 immune checkpoint inhibitor commonly used for the treatment of solid organ and hematological malignancies. Severe infusion reaction due to nivolumab is quite rare. CASE: We report a case of severe infusion reaction due to nivolumab necessitating ICU admission and...
में बचाया:
| में प्रकाशित: | Cancer Rep (Hoboken) |
|---|---|
| मुख्य लेखकों: | , , , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
John Wiley and Sons Inc.
2020
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7941420/ https://ncbi.nlm.nih.gov/pubmed/32671983 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cnr2.1246 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|